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Abstract
Background: New highly pathogenic H5N1 influenza viruses are continuing to evolve with a potential threat for an
influenza pandemic. So far, the H5N1 influenza viruses have not widely circulated in humans and therefore constitute a high
risk for the non immune population. The aim of this study was to evaluate the cross-protective potential of the
hemagglutinins of five H5N1 strains of divergent clades using a live attenuated modified vaccinia Ankara (MVA) vector
vaccine.
Methodology/Principal Findings: The replication-deficient MVA virus was used to express influenza hemagglutinin (HA)
proteins. Specifically, recombinant MVA viruses expressing the HA genes of the clade 1 virus A/Vietnam/1203/2004 (VN/
1203), the clade 2.1.3 virus A/Indonesia/5/2005 (IN5/05), the clade 2.2 viruses A/turkey/Turkey/1/2005 (TT01/05) and A/
chicken/Egypt/3/2006 (CE/06), and the clade 2.3.4 virus A/Anhui/1/2005 (AH1/05) were constructed. These experimental live
vaccines were assessed in a lethal mouse model. Mice vaccinated with the VN/1203 hemagglutinin-expressing MVA induced
excellent protection against all the above mentioned clades. Also mice vaccinated with the IN5/05 HA expressing MVA
induced substantial protection against homologous and heterologous AH1/05 challenge. After vaccination with the CE/06
HA expressing MVA, mice were fully protected against clade 2.2 challenge and partially protected against challenge of other
clades. Mice vaccinated with AH1/05 HA expressing MVA vectors were only partially protected against homologous and
heterologous challenge. The live vaccines induced substantial amounts of neutralizing antibodies, mainly directed against
the homologous challenge virus, and high levels of HA-specific IFN-c secreting CD4 and CD8 T-cells against epitopes
conserved among the H5 clades and subclades.
Conclusions/Significance: The highest level of cross-protection was induced by the HA derived from the VN/1203 strain,
suggesting that pandemic H5 vaccines utilizing MVA vector technology, should be based on the VN/1203 hemagglutinin.
Furthermore, the recombinant MVA-HA-VN, as characterized in the present study, would be a promising candidate for such
a vaccine.
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Introduction
Influenza A viruses infect, among other hosts, aquatic birds,
poultry, swine and humans [1]. Whereas in aquatic birds the
infection is asymptomatic, in humans influenza infection can cause
severe symptoms. The highly pathogenic avian influenza (HPAI)
viruses are considered candidates for a new pandemic. H5N1 is
one of the most pathogenic subtypes and has caused more than
500 symptomatic infections worldwide, of which more than 300
were lethal [2]. So far, the H5N1 influenza subtype has not
circulated in the human population. If H5N1 influenza viruses
become transmittable from human-to-human a new pandemic is
likely to occur. Therefore, the development of safe and effective
vaccines has high priority. Since the exact subtype and clade of a
potential future pandemic strain is not known, broad cross-
protection is a highly desirable feature of any pre-pandemic
vaccine. The key to successful vaccine design is understanding the
cross-reactivity between the genetically distinct H5N1 strains.
As described in previous studies, inactivated vaccines containing
the HA of clade 1 and 2.1 H5N1 influenza viruses display
significant cross protective potential [3–5]. Cross-clade protection
was also shown previously using virus like particles (VLPs)
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[5,6]. Furthermore, non-replicating vaccinia vectors including
MVA may be a good alternative for cross reactive pandemic
influenza vaccines. MVA is a highly attenuated strain of vaccinia
virus with a long-standing safety record [7,8] expressing foreign
genes efficiently and inducing effective immune responses [9,10].
In previous studies, a clade 1 MVA-H5 vaccine could protect mice
against challenge with a clade 2.1 virus [11,12] and the same
vector conferred protection against homologous and heterologous
H5N1 influenza virus infections also in macaques [13,14].
Furthermore, a candidate clade 1 H5N1 vaccine based on
defective vaccinia induced complete protection from lethal
homologous virus challenge and also full cross-protection against
clade 0 and 2 challenge viruses [15] and a pandemic H1N1 live
vaccine based on MVA was highly immunogenic and protected
mice in active and passive immunizations [16].
This study extends previous findings by investigating also the
cross-protective potential of the HAs of more distantly related H5
viruses including clades 2.2 and 2.3.4 represented by the strains A/
turkey/Turkey/01/05, A/Chicken/Egypt/3/06 (clade 2.2.) and
A/Anhui/1/2005 (clade 2.3.4). This is particularly important,
because the current focus of H5N1 activity is Egypt. In 2009 and
2010 more than 50% of cases worldwide have occurred in this
country. To allow for direct comparison, the different HA genes
were expressed by MVA vectors that were used as experimental
live vaccines against H5N1 challenge. Protection of mice and
induction of antibodies were analyzed after single dose vaccina-
tions. Additionally, the role of T cell responses in cross-protection
was analyzed.
Materials and Methods
Ethics statement
All animal experiments were reviewed by the Baxter Bioscience
Institutional Animal Care and Use Committee (IACUC Vienna/
Orth) and approved by internal animal welfare officers (Experi-
ment ID 08/06/NO ¨ ). Animal experiments were conducted in
accordance with Austrian laws on animal experimentation and
approved by Austrian regulatory authorities (permit number the
Government of Lower Austria, LF1-TVG-25/010-2006). Exper-
iments were conducted according to guidelines set out by the
Association for Assessment and Accreditation of Laboratory
Animal Care International (AAALAC). Animals were housed
according to EU guidelines, in housing facilities accredited by the
AAALAC.
Cells and viruses
DF-1 (CRL-12203) cells were obtained from the American Type
Culture Collection (ATCC). Cells were cultivated in DMEM
(Biochrom AG) containing 5% fetal calf serum (FCS). Chicken
e m b r y oc e l l s( C E C )w e r ep r o d u c e di nh o u s ea n dc u l t i v a t e di n
Med199 (Gibco, Inc.) containing 5% fetal calf serum (FCS). The influ-
enza viruses A/Vietnam/1203/2004 (H5N1, CDC #2004706280)
and A/Indonesia/5/05 (H5N1, CDC #2005740199) were kindly
provided by the Centers for Disease Control and Prevention (CDC,
Atlanta, USA). The A/turkey/Turkey/1/05(H5N1) virus was kindly
provided by National Institute for Medical Research (NIMR). The
influenza A/Anhui/5/2005 strain was generated by reverse genetics
procedures and was provided by Green Hills Biotechnologies,
Vienna. The vaccinia virus strain Lister/Elstree (VR-862) was
obtained from the ATCC. The basis of the Lister constructs was
the subcloned virus vpDW-862/Elstree. The MVA strain (MVA
1974/NIH clone 1) was kindly provided by B. Moss (National
Institutes of Health).
Cloning of the hemagglutinin genes
pHA-mH5-HA-VN and pHA-mH5-HA-IN. For cloning the HA
gene of A/Vietnam/1203/2004 (Accession number AY818135) the
plasmid pDD4mH55TNT-VN-HA [15] was used. For cloning the
HA gene of A/Indonesia/5/07 (HA-IN, Los Alamos data base
ISDN125873) the pPCR-Script-HA-IN [15] was used. The HA-IN
gene was placed downstream of an early/late promoter in pDD4-
mH5-5TNT resulting in pDD4-mH5-HA-IN. The pDD4-mH5-
5TNT is a recombination plasmid directing the D4/D5 intergenic
region of vaccinia virus. It codes for the essential D4R gene in
reverse orientation. Foreign genes cloned into the multiple cloning
site of pDD4-mH5-5TNT will be expressed under the synthetic
early/late promoter mH5 [17]. The vectors contain also the
vaccinia virus stop-signal TTTTTNT (5TNT) [18]. The HA-
expression cassettes were amplified by PCR using the primer
o.MVA-1 (59-TTT CAC TAA AGC TGC GGC CG-39)a n d
o.MVA-2 (59-CCG AAA CGC CGT TAA CAA AA-39) from the
templates pDD4mH55TNT-VN-HA or pDD4-mH5-HA-IN and
ligated in pHA-vA by using Eco105I (Fermentas). The final
constructs were characterized by restriction enzyme analysis and
verified by sequencing. pHA-mH5-HA-AN, pHA-mH5-HA-CE and
pHA-mH5-HA-TT. The HA-sequences of the A/Anhui/1/
2005(H5N1) strain (accession number DQ371928) and the A/
chicken/Egypt/3/2006(H5N1) strain (Accession number EU146866)
were chemically synthesized (Geneart, Inc., Regensburg, Germany).
Each fragment was cloned into the plasmid pER-mH5-PL [19]
using NcoI and XmaI restriction sites, resulting in pER-mH5-HA-
AN or pER-mH5-HA-CE. The plasmid pER-mH5-PL was
obtained by insertion of the vaccinia virus promoter mH5, a
vaccinia virus stop signal (TTTTTNT) and a multiple cloning site
(StuI, NcoI, PvuII, SpeI, HindIII, SacI, XmaI, SalI, NotI) into
plasmid pER that directs the gene cassette into the D4/D5
intergenic region [19]. The RNA of Influenza A/turkey/Turkey/
1/2005 (H5N1, Accession number EF619980) was isolated and
used for cDNA synthesis with the primer o.FluRT-2 (59-AGC AAA
AGC AGG GGT ATA ATC TGT C-39). PCR was performed by
using the primers o.HAv-10 (59-ACC ATG GAG AAA ATA GTG
CTT C-39) and o.HAu-2 (59-GTC GAC TTA AAT GCA AAT
TCT GCA TTG TAA C-39) from this cDNA. The PCR-fragment
wascloned inpDD4-mH5-5TNTbyusingNcoIandSalIrestriction
sites, resulting in pDD4-mH5-HA-TT. The HA-expression cas-
settes were amplified by PCR using the primers o.pER-mH5 59
XhoI (59-GAC TCT CG AGG CAG CTA GCA AAA ATT GAA
A3 9-) and o.pER-39 BamHI (59-GTA TGG ATC CAA ATT TCA
CTA AAG CTG CGG-39) from pER-mH5-HA-AN, pER-mH5-
HA-CE and pDD4-mH5-HA-TT, respectively. The PCR-frag-
ments were cut using restriction enzymes XhoI and BamHI and
ligated in pHA-vA by using the same restriction sites. The final
constructs were characterized by restriction analyses and verified by
sequencing of the inserted DNA.
Construction of recombinant MVA
MVA-mH5-HA-VN, MVA-HA-IN, MVA-HA-AN, MVA-HA-CE,
MVA-HA-TT. Twenty micrograms of pHA-mH5-HA-VN, pHA-
mH5-HA-IN, pHA-mH5-HA-AN, pHA-mH5-HA-CE, or pHA-
mH5-HA-TT plasmid DNA were transfected into MVA infected
primary chicken cells (CEC) by calcium phosphate precipitation
and further processed as described previously [20]. The purified
recombinant virus isolates were expanded for large-scale prepa-
rations in CEC.
MVA titration by plaque-assay
The virus stocks were characterized by defining the virus
amounts in 1 ml stock solution. Plaque titrations of recombinant
MVA-Based Pandemic Influenza Vaccine
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made and used for infection DF-1 cells cultivated in six well plates.
Two wells per plate were infected with the same virus dilution.
Three days after infection, plaques were stained using 0.1% crystal
violet dissolved in a 20% ethanol solution. The titer was calculated
by number of plaques multiplied by dilution.
SDS-Page and Western Blot
Expression of the HA proteins by MVA was detected by
Western blotting. DF-1 cells were infected with a MOI of 0.1 for
48 hours. Infected cells were harvested by scraping and mixed
with 2x Laemmli buffer (Fermentas, Inc.). To separate the proteins
the cell lysates were loaded on 12% Tris-gels (BioRad, Inc)
together with molecular weight standards (PageRuler
TM Pre-
stained Protein Ladder; Fermentas). After transfer to a nitrocel-
lulose membrane (Invitrogen, Inc), total protein was stained with
Ponceau-S-Solution (Sigma, Inc). The HA proteins were detected
with a 1:1000 solution of a sheep antiserum against the A/
Vietnam/1194/04 (H5N1) hemagglutinin (National Institute for
Biological Standards and Control, NIBSC 04/214). A 1:2000
dilution of a donkey-anti-sheep alkaline phosphatase-conjugated
IgG (Sigma Inc) was used as a secondary antibody.
Double immunostain assay
DF-1 cells were infected with 10, 100 and 1000 pfu of
recombinant MVA. The infection was overlaid with 3%
carboxymethyl cellulose (CMC, Sigma, Inc). After 4 days
infection, the cells were fixed with methanol/acetone solution.
The HA-Protein was stained using a 1:1000 solution of a sheep
antiserum against the A/Vietnam/1194/04 (H5N1) hemaggluti-
nin (National Institute for Biological Standards and Control,
NIBSC 04/214) as first antibody and an anti sheep IgG, HRP
conjugated antibody (Sigma, Inc.) as second one. The HA-Protein
staining was done with a DAB-staining kit (Vector Lab) containing
nickel resulting in black-grey colored plaques. Afterwards the
vaccinia virus proteins in recombinant MVA infected cells were
stained. The vaccinia virus proteins were detected by a rabbit anti
vaccinia virus sera (produced in house, Baxter) as first antibody
and with a peroxidase-conjugated goat anti rabbit antibody
(Sigma, Inc) as second antibody. The staining was performed with
a DAB staining solution kit (Vector Lab) without nickel. This
staining resulted in brown staining distinguishable from the black-
grey stained plaques.
Particle Infectivity (PI) Ratio
The particle infectivity (PI) ratio, as a parameter for quality of a
virus stock, was determined as described elsewhere [21]. Briefly,
real-time PCR was used to determine the amount of MVA gene
copies (genomic equivalents) and set in relation with the plaque
forming units (pfu) of the stock.
Protection/challenge experiments
Groups of 6 female Balb/c mice (6 to 7 weeks old, Charles
River) were immunized intramuscularly once with 10
6 pfu of
recombinant MVA virus. Control groups were immunized with
10
6 pfu wild-type (wt) MVA virus or with buffer. Blood samples
were taken for IgG ELISA and HI titer determinations on days 20
and 41. Mice were challenged intranasally with 1610
5 TCID50/
ml of the respective influenza viruses (A/Vietnam/1203/2004, A/
Indonesia/5/05, A/Anhui/5/2005, or A/turkey/Turkey/1/05)
on day 42 and monitored over 14 days. Symptoms including
ruffled fur (score of 1), curved posture (score of 2), apathy (score of
3), and death (score of 4) were recorded. As outlined in ref. [15],
the virus dose that kills 50% of the mice (LD50) is 24 TCID50 for
the A/Vietnam/1203/2004, 18 TCID50 for A/Indonesia/5/07,
9 TCID50 for A/Anhui/5/2005 and 11 TCID50 for the A/
turkey/Turkey/1/05 strain.
Immunization experiments for cellular immunity.
Groups of 5 female Balb/c mice (6 to 7 weeks old, Charles
River) were immunized intramuscularly twice (days 0, 21) with
10
6 pfu of recombinant MVA virus. Control groups were
immunized with 10
6 pfu wild-type (wt) MVA virus or with buffer.
Spleens were obtained for IFN-c analyses on day 28 post-
immunization after euthanizing the mice.
ELISA (enzyme linked immunosorbant assay)
The ELISA assay was done as described elsewhere [3]. Briefly,
the ELISA titer was measured against recombinant H5 (rHA-H5
A/Vietnam/1203/2004, Protein Sciences Corporation). All sera
were serial diluted in four-fold steps starting with 1:100 dilution
(1:100 to 1:409,600). After incubation with the HRP-labeled
secondary anti-mouse IgG antibody (Sigma, Inc.) and color
development using OPD/H2O2 plates were read at 490/
620 nm. The antibody titer of the serum samples determined as
reciprocal of the dilution step, which was equal or greater than the
cut-off value. The cut-off value was four times the mean
absorbance value of a negative control serum at a 1:100 dilution.
Micro neutralization (mNT) assay
The mNT assay was performed as described elsewhere [3].
Briefly, sera were serially diluted in two-fold steps. The diluted sera
were mixed with the respective virus strains (A/Vietnam/1203/
2004, A/Indonesia/5/05, A/Anhui/5/2005, or A/turkey/Tur-
key/1/05) at a concentration of 100 TCID50 per well, and
transferred to a monolayer of Vero cells [22]. Five days post
incubation, Vero cells were inspected for cytopathic effects. The
neutralizing antibody titer was defined as the reciprocal serum
dilution at which virus growth was 50% inhibited and was
calculated by the method of Reed and Muench [23].
T-cell IFN-c analysis
Flow cytometric intracellular IFN-c staining was used to
determine frequencies of hemagglutinin-specific CD4 and CD8
T-cells in Balb/c mice 7 days after the second immunization as
described previously [15]. Pooled splenocytes from 5 animals were
analyzed in two independent immunization experiments. In each
case, single cell suspensions of splenocytes were stimulated
overnight in the presence of 10 mg/ml brefeldin A (Sigma) with
3 mg hemagglutinin per ml of inactivated whole virus antigens
(H5N1/Vietnam/1203/2004, H5N1/Indonesia/5/05, H1N1/
California/07/2009), or with two peptides from hemagglutinin
(HA140-154, HA189-197) at 2 mg/ml per peptide. The 9-mer
peptide HA189-197, IYSTVASSL, contains the immune domi-
nant, H2-Kd restricted CD8 T-cell epitope that is highly
conserved within the H1 or H5 hemagglutinins and is located in
the HA2 subunit [24]. The 15-mer HA140-154 peptide,
KSSFFRNVVWLIKKN, represents the dominant H2-d restricted
CD4 T-cell epitope within the H5 hemagglutinin of the H5N1/
Vietnam/1203/2004 strain. Cells were then incubated with
LIVE/ Dead Violet Kit (VIVID, Molecular Probes) subsequently
stained with rat anti-mouse CD4-APC and CD8-APC H7
antibodies and, after permeabilization with 0.08% saponin
(Sigma), with rat anti-mouse IFN-c FITC and CD3-PerCP
antibodies (all BD Biosciences). At least 100 000 viable cells were
acquired on a FACSCanto-2 (BD Biosciences), and analyzed using
MVA-Based Pandemic Influenza Vaccine
PLoS ONE | www.plosone.org 3 January 2011 | Volume 6 | Issue 1 | e16247FlowJo software (Tree Star, Inc.). Percentages of IFN-c producing
T-cells were calculated after gating on VIVID negative, CD3
positive, CD4 or CD8 positive lymphocytes.
T-cell epitope screen
One hundred eleven fifteen-mer peptides covering the whole
H5/Vietnam hemagglutinin with an overlap of 5 amino acids
were synthesized using tri-fluoroacetate as counterion (JPT
Peptide Technologies GmbH, Germany). Purity of the peptides
was .90% in all cases, and identity of the peptides was verified by
mass spectrometry. Splenocytes obtained from Balb/C mice after
2 immunizations with vaccinia virus expressing H5 hemagglutinin
of H5N1/Vietnam/1203/2004 were used to identify those
peptides which could induce specific IFN-c CD4 or CD8 T-cell
responses upon restimulation by FACS analysis as described
above.
Statistical analysis
For statistical analysis of survival differences between animal
groups, the Kaplan Meyer log rank test of GraphPad Prism
software (San Diego, CA) was used. Data of viral micro NT,
ELISA IgG titers and clinical score were analyzed using the one-
way ANOVA and Tukeys Multiple Comparison Test. All
differences were considered significant at P,0.05.
Results
Construction and characterization of MVA viruses
expressing different H5 hemagglutinins
According to the standard nomenclature system based upon the
evolution of the H5 hemagglutinin genes, the H5N1 influenza
viruses are grouped in different clades [25]. Within one clade the
nucleotides must not differ more than 1.5%. In this study, the HA
genes of five different clades with 95 to 99% identity on protein
level were used to analyze cross protection in a mouse model. The
influenza strains used and the amino acid identities are depicted in
Table 1. The CE3/06 and TT01/05 hemagglutinins, for
instance, differ only by one amino acid, whereas the IN5/05
and TT01/05 strains share only 95% identity.
For construction of the recombinant viruses, the HA genes were
each inserted into the genomic 165R locus of MVA [26] by in-vivo
recombination techniques (see methods) resulting in five candidate
vaccines. The different HA genes were placed downstream of a
strong vaccinia early/late promoter [17] and were optimized for
expression by vaccinia virus removing internal RNA transcription
stop signals [18]. Viruses were grown in primary chicken cells and
purified by centrifugation through a sucrose cushion. All
preparations had similar titers in the range of 5–8610
9 pfu/ml.
Furthermore, the particle-to-infectivity ratio, determined by
measuring the relation between genomic equivalents by real-time
PCR and live virus by plaque assay, was similar among the
recombinant viruses indicating comparable infectivity of the virus
preparations (Table 2).
To test for purity of the recombinant viruses, a double
immunostain assay was performed. As described in methods,
plaques were first stained against the influenza HA proteins
(resulting in brown plaques) and afterwards against vaccinia virus
proteins (resulting in black plaques in the wild-type viruses or
nonexpressing mutants only) allowing us to distinguish HA-
expressing viruses from non-expressing contaminants. As a control
a mixture of recombinant and wild-type viruses was used. All
recombinants were positive for the influenza HA and non-HA-
expressing viruses were not detected (not shown). From this
analysis it was concluded that all of the recombinant MVAs
express the HA protein (Table 2). The genomic structure of the
recombinant MVA viruses was confirmed by PCR analysis. A
primer set flanking the insertion site of the foreign genes was used
to show that the recombinant viruses had the expected enlarged
fragment and were free of wild-type virus. An additional primer set
with one specific primer binding within the foreign gene and one
binding at the insertion site was used to identify the HA gene in
the insertion locus (not shown).
Expression of the hemagglutinins in chicken cells
The correct expression of the influenza HA by the recombinant
MVAs was analyzed by Western blotting. For this purpose the
permanent chicken cell line DF-1 [27] was used. The cells were
infected with a MOI of 0.1 and cell lysates were prepared 72 hrs
post infection. The recombinant MVAs that express the different
hemagglutinins were analyzed in a Western blot using an anti-
influenza A/Vietnam/1194/04 (H5N1) polyclonal serum for
detection (Fig. 1). Ponceau-S staining was used to assure that
the total protein content in all lanes was equivalent after the
transfer. The Western blot demonstrates that all recombinants
express the influenza hemagglutinin, and that efficient processing
of the protein takes place, resulting in similar bands (HA0, HA1,
and HA2) as seen with the influenza control (compare lane 2 and
lanes 3–7). The large band at 80 kDa represents residual
uncleaved HA0. The lower bands around 55 and 26 kDa
represent the HA1 and HA2 subunits. Due to the presence of a
polybasic cleavage site in the H5 hemagglutinins, efficient cleavage
is achieved also in non-respiratory epithelial cells, like the DF-1
cell line. The double band (in the 26 kDa size range) is presumably
due to glycosylation variants of the HA2 subunit in the total cell
lysates.
Cross protection of mice from lethal challenge
A single dose immunization scheme was used to detect
differences in protection among the HA proteins of the different
clades. In pre-experiments it was found that double dose
immunization results in robust protection, which precludes the
detection of subtle differences in cross protection. To assess cross
protection with the five MVA-based experimental vaccines, Balb/
c mice were immunized once i.m. with a dose of 1610
6 pfu/
animal and challenged intranasally 42 days later with the
homologous or heterologous influenza wild-type strains. Two
separate cross protection experiments were performed. In the pre-
Table 1. Amino acid sequence identities of influenza HA
proteins of strains used in this study.
clade
Influenza
strain Identity between different strains in %
VN/1203 IN5/05 CE3/06 TT01/05 AH1/05
1 VN/1203
(1) 1 0 0 9 69 69 69 6
2.1.3 IN5/05
(2) 96 100 95 95 96
2.2. TT01/05
(3) 96 95 99 100 96
2.2. CE3/06
(4) 96 95 100 99 96
2.3.4 AH1/05
(5) 96 96 96 96 100
(1)VN/1203, A/Vietnam/1203/2004(H5N1);
(2)IN5/05, A/Indonesia/5/05(H5N1);
(3)TT1/05, A/turkey/Turkey/1/2005(H5N1);
(4)CE3/06, A/Chicken/Egypt/3/2006(H5N1);
(5)AH1/05, A/Anhui/1/2005(H5N1).
doi:10.1371/journal.pone.0016247.t001
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ELISA (see materials and methods). Neutralizing antibodies were
assayed separately against each of the challenge strains (with the
exception of the CE/06 strain, which was not available). The
results, are presented in Table 3. Since the lethal dose 50 (LD50)
of all H5N1 wild-type strains in Balb/c mice was similar (range 9–
24 TCID50 per animal; see methods) a uniform challenge dose of
1610
5 pfu/animal was chosen for all strains. Survival and clinical
scores were monitored over a period of 14 days and are depicted in
Figs. 2 and 3).
The MVA-HA-VN candidate vaccine induced excellent protec-
tion from death against all clades (Table 3A, Fig. 2A). After
challenge with the homologous VN/1203 strain all animal
survived and very few clinical symptoms were recorded
(Fig. 3A). With the more distantly related Turkey/turkey and
Anhui strains, full survival with some minor clinical symptoms was
seen. Against challenge with the Indonesia strain 92% survival was
achieved. The IgG titer induced by immunization (geometric
mean titer, GMT, from two determinations) was high. Neutral-
izing antibodies, using the different H5N1 viruses in the NT assay,
were measurable, with the exception of the Anhui strain, which
represents the most distant clade of the tested viruses.
The results obtained after immunization with the MVA-HA-IN
vaccine are shown in Table 3B and Figs. 2B and 3B. This
vaccine induced full protection from death against homologous
challenge and against the heterologous Anhui strain with some
minor clinical symptoms. Survival was 92% after challenge with
the VN/1203 strain, however, only 67% of the animals survived
challenge with the more distant (clade 2.2) TT01/05 strain.
Neutralizing antibodies were higher against the homologous virus
and lower against the strains of the other clades.
Animals that had received the vaccine based on the TT01/05
strain, MVA-HA-TT (Table 3C and Figs. 2D and 3D), showed
almost full survival (92%) with low clinical scores, while survival
after challenge with the most distant VN/1203 virus was only 75%,
and stronger clinical symptoms were seen. Protection from death
against the more related clades IN5/05 and AH1/2005 was 83%.
Neutralizing antibodies were elevated against the homologous
TT01/05wt virus used in the NT assay, and lower against the IN5/
05 virus and below detection in the distantly related viruses.
Table 2. Recombinant MVA viruses used for immunizations.
recombinant virus HA gene of the strain (accession number) recombination plasmid
(1) Titer
(2) (pfu/ml) PI-ratio
(3) HA exp. (%)
(4)
MVA-HA-VN A/Vietnam/1203/2004 (AY818135) pHA-mH5-HA-VN 8.4610
9 58 100
MVA-HA-IN A/Indonesia/5/05 (ISDN125873) pHA-mH5-HA-IN 6610
9 45 100
MVA-HA-TT A/turkey/Turkey/1/05 (EF619980) pHA-mH5-HA-TT 5.1610
9 54 100
MVA-HA-CE A/Chicken/Egypt/3/2006 (EU146866) pHA-mH5-HA-CE 5.4610
9 34 100
MVA-HA-AN A/Anhui/1/2005 (DQ371928) pHA-mH5-HA-AN 5.8610
9 20 100
(1)All HA genes are controlled by the vaccinia virus mH5 promoter;
(2)titers of sucrose-purified virus preparations from CEC cells (see methods);
(3)particle infectivity ratio, ratio of genomic equivalents determined by qPCR to infectious virus particles (pfu);
(4)HA expression as determined by immunostaining (see methods).
doi:10.1371/journal.pone.0016247.t002
Figure 1. Western blot of chicken cell lysates tested for influenza virus HA expression. Lane 1, protein ladder, size in kDa; lane 2, positive
control, 0.5 mg of formalin inactivated purified influenza virus A/Vietnam/1203/2004 H5N1. Lane 3, MVA-HA-VN. Lane 4, MVA-HA-IN. Lane 5, MVA-HA-
TT. Lane 6, MVA-HA-CE. Lane 7, MVA-HA-AN. Lane 8, negative control, empty vector MVA wt. For abbreviations see Table 2. All recombinant MVAs
(lanes 3–7) express the HA0 (band around 80 kDa), the HA1 (band around 55 kDa, and the HA2 (band around 25 kDa). The specific HA bands co-
migrate with the ones of the positive control (lane 2) and are absent in the negative control (lane 8).
doi:10.1371/journal.pone.0016247.g001
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conferred full protection from death against challenge with the
most closely related clades, TT and Anhui (Table 3D and
Figs. 2C and 3C). Although all mice developed clinical
symptoms within three days post challenge, this was not associated
with substantial lethality. The vaccine was partially protective
against the more distant clades (IN and VN) with maximal survival
rates of 75% and higher clinical scores. Since no wt CE virus was
available, homologous challenge could not be carried out.
Neutralizing antibodies were detectable against the TT01/05
strain and were below the detection limit with the other strains.
The protection profile of the clade 2.3.4 Anhui based
recombinant, MVA-HA-AN, was similar to the TT recombinant,
with 92% survival after homologous challenge and maximal 83%
cross protection from death against the other clades (Table 3E
and Figs. 2E and 3E). Although IgG ELISA antibodies were
high, no neutralizing antibodies were detectable. Also, neutraliza-
tion of the homologous virus was moderate, consistent with the
protection results. All mice in the control groups immunised with
MVA wt (Tab. 3F, Figs. 2F and 3F) or with PBS (Tab. 3G,
Figs. 2G and 3G) were not protected. From day two on infected
mice developed severe clinical symptoms and died within 6 and 10
days. Consistent with this finding, the ELISA and NT titers were
below the detection limits.
T-cell responses induced by the MVA-based vaccines
Vaccine-specific T-cell responses were determined by intracel-
lular cytokine staining and FACS analyses. First, a T-cell epitope
screen with 15-mer peptides covering the whole H5/Vietnam
hemagglutinin with an overlap of 5 amino acids was used to
identify those peptides within HA which elicit a CD4 or CD8 T-
cell response after vaccination with vaccinia-based live vaccines.
As expected, a single peptide (HA185-199 QILSIYSTVASSLAL)
completely represented the CD8 response induced by a peptide
pool containing all 111 peptides (data not shown), as this peptide
contains the IYSTVASSL motif, the immune dominant, H2-Kd
restricted CD8 T-cell epitope that is highly conserved within the
H1 or H5 hemagglutinins and which is located in the HA2
Table 3. Protection of mice from death, clinical score and serology results after single dose vaccination with MVA H5
recombinants.
Vaccine virus
(1) Challenge virus
(2) Survival n/nt
(3) (%) clinical score
(4) (day 8/d14) IgG [GMT] mNT [GMT]
A MVA-HA-VN
(5) VN/1203 12/12 (100) 0/0 4525 62
IN5/05 11/12 (92) 0.84/0.34 17
TT01/05 12/12 (100) 0.75/0.09 28
AH1/2005 12/12 (100) 0.25/0 ,14
B MVA-HA-IN VN/1203 11/12 (92) 1.25/0.59 1345 ,7
IN5/05 12/12 (100) 0.42/0 80
TT01/05 8/12 (67) 1.84/1.33 28
AH1/2005 12/12 (100) 0.67/0 13
C MVA-HA-TT VN/1203 9/12 (75) 1.92/1.34 1345 ,7
IN5/05 10/12 (83) 0.67/0.67 13
TT01/05 11/12 (92) 0.5/0.34 67
AH1/2005 10/12 (83) 1.17/0.67 ,7
D MVA-HA-CE
(5) VN/1203 8/12 (67) 1.67/1.75 3805 ,7
IN5/05 9/12 (75) 2.17/1.75 ,14
TT01/05 12/12 (100) 0.34/0.25 37
AH1/2005 12/12 (100) 0.92/0.09 ,14
E MVA-HA-AN VN/1203 9/12 (75) 2.25/1.92 4525 ,7
IN5/05 10/12 (83) 1.34/0.84 17
TT01/05 8/12 (67) 2.09/1.92 12
AH1/2005 11/12 (92) 0.36/0.33 22
F MVA VN/1203 0/12 (0) 4/4 ,100 ,7
IN5/05 0/12 (0) 3.75/4 ,7
TT01/05 0/12 (0) 4/4 ,7
AH1/2005 0/12 (0) 3.92/4 ,7
G PBS VN/1203 0/12 (0) 3.67/4 ,100 ,7
IN5/05 0/12 (0) 3.5/4 ,7
TT01/05 0/12 (0) 4/4 ,7
AH1/2005 0/12 (0) 4/4 ,7
(1)Mice were vaccinated once with 10
6 pfu of recombinant MVA or wt MVA; for abbreviations see Tables 2 and 3;
(2)challenge dose, 1610
5 TCID50; for abbreviations see Table 1;
(3)n/nt, number of survivors/total animals of two separate experiments with 6 animals per group;
(4)clinical score at day 8 (peak)/day 14 (the end of experiment) after challenge. Each number represents the arithmetic mean from 12 animals;
(5)final serum dilutions in mNT assay were 1:20 (dl 14), in all other sera 1:10 (detection limit ,7).
doi:10.1371/journal.pone.0016247.t003
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cells directed against the HA of the VN/1203 strain also
specifically recognized a single peptide, identified as the 15-mer
HA140-154 peptide KSSFFRNVVWLIKKN. This peptide is
well conserved among the H5 variants but not in H1 (Table 4)
and was unable to restimulate HA-1/CA/07 specific CD4 T-cells
(data not shown).
To compare the efficiencies of the various MVA based vaccines
to induce influenza-specific T-cell responses, groups of Balb/c
mice were immunized in a two-dose regimen on days 0 and 21
with 10
6 pfu of the recombinant MVA virus vaccines or the wild-
type MVA control, and spleens were collected on day 7 after the
first or second second immunization. Whole viral antigens from
H5N1 of different clades, i.e. VN/1203 and IN5/05, and from
H1N1/California (CA/07) were used for re-stimulation of the
splenocytes to investigate the induction of cross-reactive cellular
immune responses. In addition, the known cross-reactive CD8 T-
cell peptide, which is not only conserved within the H5 strains, but
Figure 2. Survival after vaccination with recombinant MVAs and challenge with different H5N1 strains. For single dose vaccinations
recombinant MVA vaccines expressing the HA of VN/1203 (A), of IN5/05 (B), of CE3/06 (C), of TT01/05 (D) and AH1/2005 (E) were used. As controls,
mice were vaccinated with wt MVA (F) or were treated with PBS (G). After challenge with wild-type H5N1 strains of the different clades, mice were
monitored for 14 days. The data represent two separate experiments with six animals per group.
doi:10.1371/journal.pone.0016247.g002
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peptide from H5/Vietnam were used. After a single immuniza-
tion, HA specific CD8 T-cell responses were readily detectable
and comparable for all H5-expressing viral vaccines, ranging
between 0.27% and 0.39%. In contrast, levels of HA-specific CD4
T-cells were generally very low being at or just above the detection
limit of the assay (0.05%). Since the inherent variability of the test
results at low response levels did not allow for accurate comparison
of the various vaccines, only the higher responses obtained after a
booster immunization were compared.
Figure 3. Clinical disease scoring after vaccination with recombinant MVAs and challenge with different H5N1 strains. MVA vaccines
expressing the HA of VN/1203 (A), of IN5/05 (B), of CE3/06 (C), of TT01/05 (D) and AH1/2005 (E) were used for vaccination. Controls included wt MVA
(F) or PBS (G). After challenge with wild-type H5N1 strains of the different clades, mice were clinically monitored for 14 days. The parameters used to
evaluate the clinical score were ruffled fur (1 point), arched posture (2 points), apathy (3 points) and death (4 points). Each data point represents the
arithmetic mean of two separate experiments with six animals per group.
doi:10.1371/journal.pone.0016247.g003
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not the H1N1/California antigen, induced strong IFN-c secretion
in CD4 T-cells of mice immunized with the experimental
recombinant vaccines. On average, between 0.6 and 0.9% of
the CD4 T-cells responded to the two H5N1 whole virus antigens
in two independent experiments. No significant difference was
observed in the reactions against the Vietnam and Indonesia
antigens. Furthermore, CD4 induction was similarly strong after
stimulation with peptide HA140-154 in all the MVA vaccine
immunization groups. The frequencies detected were only slightly
lower than those found when using the whole viral antigens,
indicating that this peptide represents the most prominent CD4 T
cell epitope present within the HA molecule. The corresponding
peptide sequence is substantially mutated in HA from H1/
California (Table 4), and is not recognized by HA/Ca-specific
CD4 T-cells induced after immunization with H1N1/California
whole viral vaccine (data not shown). As expected, the CD8 T cell-
specific 9-mer peptide HA189-197 did not stimulate any CD4 T-
cell responses, nor did the MVA wild-type virus induce detectable
frequencies of influenza-specific CD4 T-cells in the mice.
When the CD8 T-cell responses were analyzed, only the 9-mer
peptide HA189-197 induced a strong IFN-c response (Fig. 4B).
Similarly, high frequencies of HA-specific CD8 T-cells were
induced by all the vaccines, with responses ranging from 2.5 to 4%
of total CD8 T-cells. Hence, there appeared to be little or no
difference in the efficiency of the various vaccines to induce CTL
Table 4. Amino acid sequences of the CD4 T cell-specific
15mer peptide HA140-154 (located in the HA1 subunit) in the
different hemagglutinins.
strain Sequence
VN/1203 K S SFFRNVVWLIKKN
IN5/05 S P -------------
TT01/05 R - ------------D
CE3/06 R - ------------D
AH1/05 T P -------------
CA/07 A K --YK-LI--v--G
doi:10.1371/journal.pone.0016247.t004
Figure 4. Induction of influenza-specific T cells by the hemagglutinin expressing live vaccines. Frequencies of antigen specific IFN-c+
CD4 T cells (A) or CD8 T-cells (B) after immunizing twice with various hemagglutinin MVA-H5 vaccines or with the MVA wild-type control, and
stimulation with protein antigens and peptides (shown on x-axis). Splenocytes were stimulated with buffer or with formalin-inactivated whole viral
antigens of H5N1 Vietnam (H5N1-VN), H5N1 Indonesia (H5N1-IN) or H1N1/California (H1N1-CA), CD4 T cell-reactive peptide HA140-154 and the CD8 T
cell-reactive peptide HA189-197. Background medium responses were subtracted, and the means +/2 standard deviation of two separate
experiments is shown.
doi:10.1371/journal.pone.0016247.g004
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when the wild-type MVA vaccine was used for immunization.
Mapping of the amino acid differences in the
hemagglutinins in a three-dimensional model
An attempt was undertaken to map and interpret the amino
acid differences in the hemagglutinins in a three-dimensional
model of the subtype 5 HA trimer of the VN1194 strain [28]. The
HA of VN/1194 differs from that of VN/1203 by only one amino
acid (T36K) and is therefore an excellent representative of a clade
1 hemagglutinin. As the 3 D structure of the VN/1194 HA is
present online (protein database, PDB ID 2IBX), interpretation
was readily feasible. All amino acids exposed on the surface of the
HA trimer were mapped in the 3D model, with the space filling
mode of the amino acid molecules chosen to display the HA trimer
(Fig. 5). All differences between the five HAs were highlighted in
yellow in one of each of the HA1 and HA2 molecule (Fig. 5A, B).
Differing amino acids exposed to the surface of the molecule are
listed in bold in Table 5. Twenty one of the 36 amino acids that
differ between the five different HAs are exposed to the surface.
Most of these differences are located at or near the receptor
binding site.
Discussion
For a direct comparison of the cross protective capacity of HA
antigens from different clades, the HA genes were engineered into
otherwise identical recombinant MVA vectors that were then used
for immunization experiments. This approach allows analysis of
the humoral immune response to the HA antigens independently
of the influenza virus background. The in-vivo expression of the
influenza surface proteins by the non-pathogenic live MVA vector
further allowed to investigate the induction of a specific cellular
immune response by the H5 hemagglutinins.
For the comparison of the humoral immune responses against
the hemagglutinins, a suboptimal immunization protocol was
used. In a previously published MVA-based immunization
approach, robust protection against homologous challenge with
10
3 TCID50 of A/Vietnam/1194/04 was found in C75BL6 mice
[12]. In our setting using Balb/c mice, a 100-fold higher challenge
dose of 10
5 TCID50 was applied to measure the different degrees
of protection achieved with the selected HA constructs. The LD50
of all employed challenge strains of influenza was similar, so that
the infection dose of 10
5 TCID50 consistently resulted in 100%
lethality among the control animals. Immunized groups were
protected to various extents, depending on the vaccine and the
challenge virus chosen. When immunized animals were challenged
with influenza viruses homologous to the HA used for immuni-
zation, 92% to 100% survival was seen, with at least some of the
animals per group displaying moderate disease symptoms.
However, when animals were challenged with influenza virus
from heterologous clades, survival rates were reduced. The best
protection against heterologous clades was conferred by MVA-
HA-VN, which expresses the HA of the clade 1 A/Vietnam/
1203/2004 strain. Similarly high cross protection was seen with
the clade 2.1.3 A/Indonesia/5/05 (IN5/05) expressing recombi-
nant MVA-HA-IN. In most cases, the degree of protection was in
agreement with distance in the phylogenetic tree. Interestingly,
Figure 5. Three dimensional pictures of the HA trimers of the avian subtype 5 hemagglutinin. Amino acids differing from the HA of VN/
1203 are marked yellow in one of the HA monomers. A and B represent two different views of the trimer. Amino acids exposed on the surface are
marked in yellow and are printed in bold in Table 5.
doi:10.1371/journal.pone.0016247.g005
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had been immunized with the clade 1 and 2.1. constructs, MVA-
HA-VN and MVA-HA-IN, survived challenge with the clade
2.3.4 A/Anhui/1/2005(H5N1) virus with minor disease symp-
toms, only 67-83% of MVA-HA-AN immunized animals survived
challenge with A/Vietnam/1203/2004(H5N1) or A/Indonesia/
5/05(H5N1). Since the vectors were equally effective in expressing
the influenza HA antigens in vivo, the differences in the cross-
protective effect are to be found in the antigenicity of the specific
HA protein, i.e. the presence of immunogenic epitopes, and in the
relation among the different clades. To assess the importance of
the humoral immune response in this live vector approach,
neutralizing antibody responses were measured against most
influenza viruses used in the challenge study. Because a suboptimal
immunization scheme was chosen to be able to discriminate the
protection results by the different immunization/challenge virus
pairs, the serological titers achieved by immunization with the
experimental live vaccines were also lower than in a robust
protective, two dose immunization regimen. Because of the low
levels of neutralizing antibodies no correlation between protection
and antibody titer could be determined.
The cellular immunity induced by the different HA antigens
was also assessed. When harvested splenocytes were stimulated
with whole virus antigens from clade 1 VN/1203, and from clade
2.3.1 IN5/05, respectively, very similar frequencies of IFN-c-
secreting CD4 T cells were observed, whereas stimulation with a
H1N1 whole virus antigen revealed no measurable cellular
immune response. Although the CD4-driven cellular immune
response plays an important role in the defense against influenza
[29], it is concluded that it does not contribute to the clade-specific
differences in protection. Measurement of T cell responses by
intracellular cytokine assay confirmed that all experimental
vaccines induced high frequencies of both CD4 T-cells, which
were specific for an HA1 epitope located within peptide HA140-
154, and CD8 T-cells, which were directed against the well-known
immune-dominant peptide HA189-197 located in the HA2
subunit. Since these responses were directed against T-cell
epitopes conserved within the H5 hemagglutinin proteins and
since influenza-specific CD4- as well as CD8 T cells can contribute
to protection against influenza infection [30], it can be speculated
that the heterologous protection observed despite the presence of
only low levels of neutralizing antibodies was, at least in part, due
to the cross-reactive cell-mediated immunity. However, as the
frequencies of cross-reactive T-cells were very similar in all groups
immunized with the MVA-based vaccines, these cells probably do
not account for the distinct cross-protective efficiencies of the
various antigens.
Numerous studies indicate an encouraging extent of cross-
neutralization between various H5N1 strains but also stress that
protection against clade 2.3 viruses may be more difficult [31].
The genetic polymorphisms between different clades of H5N1
viruses from 2002 to 2007 were extensively analyzed in a further
publication, indicating that among others, HA residues at positions
86, 124, 129, 189, 212 and 263 constitute important antigenic sites
(defined in HI assays) and that manipulation of these sites can
improve cross-clade antigenic reactivity among diverse H5N1
strains [32]. Although VN/1203 differs in most of these positions
from the other isolates analyzed it has nevertheless induced the
best cross-protection in our study. Interestingly, recombinant
MVAs expressing the HAs of strains CE3/06 and TT01/05,
which exhibit D154, N155 and A156 residues and therefore do not
carry a glycosylation motif in this region [33], show a tendency to
Table 5. Differences in the HA amino acid sequence compared to the VN/1203 master sequence.
…3 6
1 … … 71 … … 83 … … 86 … … 94 … … 124 … … 129 … … 138 … 140 141 … … 154 155 156 …
VN
3 - K
2 -- I -- A -- V -- D --S - - L --Q - KS-- NST-
IN - T -- I -- A -- T -- S --D - - S --L - SP-- NST-
CE - T -- L -- I -- A -- N --D - - S --Q - RS-- DNA-
TT - T -- L -- I -- A -- N --D - - A --Q - RS-- DNA-
AN - T - -I- -A -- A - -N - - D --S --Q - T P - -N N T -
… 162 … … 174 … … 181 … … 189 … … 200 … … 212 … … 227 … … 235 … … 252 … … 263 … 265 … … 269 …
VN - R -- V -- P -- K -- V -- R -- E -- P -- Y -- T - M-- L -
IN - K -- V -- P -- R -- I -- K -- E -- P -- Y -- A - M-- L -
CE - R -- V -- P -- R -- V -- K -- E -- S -- N -- T - M-- L -
TT - R -- V -- P -- R -- V -- K -- E -- P -- N -- T - M-- L -
AN - R -- I -- S -- K -- V -- K -- D -- P -- Y -- A - V -- V -
… 282 … … 309 310 … … 322 323 … 325
4 … … 143
5 … … 152 … … 158 … … 183 … … 203 … … 207 …
VN - M -- NR-- Q R - R -- K -- V -- D --T -- V -- S -
IN - M -- NR-- Q R - S -- K -- I -- N --I -- M -- S -
CE - I -- NR-- Q G - R -- R -- V -- D --I -- V -- F -
TT - I -- SR-- Q G - R -- R -- V -- D --I -- V -- S -
AN - I -- NK-- L R - R -- K -- V -- D --I -- V -- S -
(1)HA1 numbering starts with the first amino acid downstream of the signal peptide with D as the first residue (Aichi numbering);
(2)amino acids exposed on the surface are printed in bold (equivalent to yellow marked molecules in Fig. 5);
(3)VN, A/Vietnam/1203/2004; IN, A/Indonesia/5/05; AN, A/Anhui/1/2005; CE, A/Chicken/Egypt/3/2006; TT, A/turkey/Turkey/1/2005;
(4)first R residue of polybasic cleavage site;
(5)numbering of the HA2 starts downstream of the polybasic cleavage site with G as the first residue.
doi:10.1371/journal.pone.0016247.t005
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AH), and vice versa. Residues at position 129 [34,35] and 94 [36]
have been described to alter receptor binding specificities but seem
to have no impact on cross-protection in our analysis. In addition,
the amino acids of the 140 s loop (positions 136 – 141), which has
been shown to be a target for neutralizing antibodies [37] and is
rather different in the analyzed HA proteins, also do not influence
cross-protection significantly. Less substitutions are found in the
stem region where more conserved antibody binding sites [38],
and conserved CD8 T cell epitopes [39,40], are located (for
instance the 9mer HA189-197 used in this study). Virus
neutralization is not only effected by antibodies that bind to the
receptor binding region, but also by antibodies binding in the
conserved HA2 region, that, for instance, block the pH-dependent
conformational change required for membrane fusion and
infectivity [38]. There were four changes in the conserved HA2
region, two of them exposed to the surface according to the 3 D
model. Interestingly, the most abundant type of mutation is a K to
R (Lys to Arg) mutation and vice versa, which occurred six times
at different locations in the HA molecules. This mutation, caused
by a single nucleotide change, is a structural change that does not
disrupt the overall protein structure and seems to be one of the
driving forces in shaping the structure of the related H5 proteins.
In general, the superiority in cross protection induced by A/
Vietnam/1204/04 hemagglutinin over the other tested hemag-
glutinins in our analysis could not be pin pointed to specific amino
acid residues, but appears to be reflected by the whole antigenic
profile of the protein. Regarding the H5 clades that were
examined in this study, an MVA vector-derived H5N1 vaccine
based on the VN/1203 strain would be the vaccine of choice.
By the use of MVA-based experimental vaccines, the cross-
protective properties of HA antigens from different clades could be
analyzed. Differences between clades were primarily attributed to
neutralizing antibodies rather than to the cellular immune
responses, because the cell-mediated immune responses were
strong, but almost uniform among the H5 antigens, independent
of the degree of homology among the clades. This finding suggests
that HA-expressing live viral vectors are capable of triggering a
strong and very broad cellular immune response against influenza
viruses of different clades. Therefore MVA-based recombinant
pandemic vaccines might represent a useful vaccine approach
against influenza viruses especially in a pre-pandemic situation
where the eventual pandemic virus target strain is not known.
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